博士伦 BLCO

Mr. Saunders has served as our Chairman of the Board and Chief Executive Officer since March 2023. He also currently serves on the board of ARS Pharmaceuticals, Inc. and as chairman of the board of Beauty Health Company (f/k/a Vesper Healthcare Acquisition Corp.) He was Co-Founder and Chairman of Vesper Healthcare Acquisition Corp., a specialty purpose acquisition company from July 2020 to May 2021. He was Chairman, President and Chief Executive Officer of Allergan and served in the role of President and Chief Executive Officer from July 2014 to May 2020 and Chairman from October 2016 to May 2020, having previously served as Chief Executive Officer and President, and as director, of Forest Laboratories, Inc., prior to its acquisition by Allergan. Prior to that, he served as Chief Executive Officer of Bausch & Lomb Incorporated, serving in this capacity from March 2010 until August 2013. Mr. Saunders also held a number of leadership positions at Schering-Plough, including the position of President of Global Consumer Health Care and was named Head of Integration for the company's merger with Merck & Co. and for Schering-Plough's acquisition of Organon BioSciences. Before joining Schering-Plough, Mr. Saunders was a partner and Head of Compliance Business Advisory at PricewaterhouseCoopers LLP. Prior to that, he was Chief Risk Officer at Coventry Health Care and Senior Vice President, Compliance, Legal and Regulatory at Home Care Corporation of America. Mr. Saunders began his career as Chief Compliance Officer for the Thomas Jefferson University Health System. In addition to his current public company director positions, he serves as a member of the board of private companies including Arena AI, Rapalogix Health, Inc., Cambrian Bio and Roam HQ Inc., where he also serves as the chairman of the board, and as a board advisor for Nextech Systems, LLC. He has also served as a member of the Executive Board of Trustees at Mount Sinai Medical Center since 2022. Mr. Saunders previously served on the boards of BridgeBio Pharma, Inc., Cisco Systems, Inc., Glo Pharma, Hugel (a semi-public company on the Korean exchange), Ocuterra Therapeutics and Osmind. Current Public Company Directorships: Pharmaceuticals, Inc. ; Beauty Health Company.

Mr. Eldessouky has served as Chief Financial Officer of the Company since January 2022. From 2021 to 2022, he served as Executive Vice President and Chief Financial Officer of BHC, and from 2016 to 2021, he served as Controller and Chief Accounting Officer of BHC. In these roles, he was responsible for overseeing global controllership functions, including financial reporting, regional finance, and global accounting policies. His role at BHC ceased in connection with the completion of the Company's initial public offering. Previously, Mr. Eldessouky served as Senior Vice President, Controller and Chief Accounting Officer of Tyco International plc from 2012 to 2016. During his tenure at Tyco, he led initiatives to redesign the controller's organization and implement an enterprise performance management framework, and he played a key role in the execution of multiple corporate transactions, including the spinoffs of Covidien and Tyco Electronics in 2006 and ADT North America and Flow Control in 2012. Earlier in his career, Mr. Eldessouky spent approximately 10 years at PwC, where he held positions of increasing responsibility, including service in PwC's National Office providing technical accounting guidance on complex accounting matters. Mr. Eldessouky has served as a member of the board of directors of TE Connectivity plc since October 2024. Mr. Eldessouky holds a Bachelor of Science in Accountancy from Ain Shams University and a Master's degree in Accounting and Finance from the University of Liverpool. He is a Certified Public Accountant (inactive) and a Chartered Global Management Accountant. He previously served as a member of the Board of Trustees of Financial Executives Research Foundation and Financial Executives International, and as a member of the Global Preparers Forum, an external advisory body to the International Accounting Standards Board, from 2007 to 2013.

Mr. Bailey has served as Chief Legal Officer of Bausch + Lomb since April 2023. He brings more than 25 years of senior executive experience and over 15 years as a chief legal officer at private and publicly traded companies in the health care industry. Mr. Bailey previously served at Bausch + Lomb from 1994 to 2013, including as Executive Vice President, Law, Policy and Communications from 2007 to 2013. He rejoined the Company from Datavant, a private health information technology company, where he served as Chief Legal Officer from 2020 to April 2023. From 2014 to 2020, Mr. Bailey was Executive Vice President, Chief Legal Officer and Corporate Secretary of Allergan plc and its predecessor companies, Forest Laboratories Inc. and Actavis plc. While at Allergan, he led the legal team that completed more than 20 public and private mergers and acquisitions, as well as multiple licensing transactions. Throughout his career, Mr. Bailey has led teams addressing a broad range of complex legal and regulatory matters, including investigations by the U.S. Securities and Exchange Commission and the U.S. Department of Justice, internal investigations, and litigation involving intellectual property, antitrust, commercial, product liability, and tax matters. Mr. Bailey began his legal career as an attorney at Nixon Peabody LLP. He has previously served as a director of TearClear, an ophthalmic pharmaceutical innovator; a member of the Board of Directors of the U.S. Chamber of Commerce Litigation Center; and a member of the Board of Trustees of the Foundation for the Morristown (New Jersey) Medical Center. He holds a Bachelor's degree from St. Olaf College and a Juris Doctor from the University of Minnesota.

Dr. Hashad has served as Executive Vice President of Research & Development and Chief Medical Officer of the Company since January 31, 2022. Previously, Dr. Hashad served as Senior Vice President and Head of R&D for Allergan Aesthetics, an AbbVie company, from May 2020 to August 2021. Prior to Allergan's acquisition by AbbVie, Dr. Hashad held a number of executive research and development positions at Allergan plc between 2010 and May 2020, including Senior Vice President and Head of Global Clinical Development from April 2019 to May 2020; Vice President and Global Head of Clinical Development, Ophthalmology, Dermatology and Medical Aesthetics from May 2017 to May 2020; and Vice President and Global Head of the Ophthalmology and Retina therapeutic areas from September 2013 to April 2019. From 2005 to 2010, Dr. Hashad served at Novartis Pharma AG as Global Program Medical Director for age-related macular degeneration programs. From 1996 to 2005, he held various positions at T3A Pharma Group. Dr. Hashad received his medical degree and a Master of Science in Medical and Surgical Ophthalmology from Cairo University and holds a business degree from INSEAD in France. He previously served on the boards of Unity Biotechnology, Inc., Applied Genetic Technologies Corporation, the Glaucoma Research Foundation, and the National Alliance of Eye and Vision Research, and served as a board adviser to the University of California, Irvine Research Center.

Ms. Bernier has served as an independent director of the Company since April 2022. She served as Chief Financial Officer and Senior Vice President, Strategic and Business Planning, of the Public Sector Pension Investment Board from August 2015 to September 2019. Previously, Ms. Bernier spent nearly 30 years as an Audit and Advisory Partner at Arthur Andersen LLP and KPMG LLP, including as Regional Managing Partner (Quebec) and a member of KPMG's Canadian Leadership Team. Ms. Bernier previously served as a director of RF Capital Group Inc., where she was Chair of the Risk Committee and a member of the Audit Committee. She currently serves as a director of Canada Enterprise Emergency Funding Corporation, where she is Chair of the Audit Committee, and of Les Proprietes Docteur Penfield Inc. Ms. Bernier holds a Bachelor of Commerce degree from McGill University and is a Fellow of the Chartered Professional Accountants of Canada.

Mr. Robertson has served as an independent director of the Company since April 2022. He previously served at BMO Financial Group, a diversified financial services organization, as Executive Vice President and Head of Anti-Money Laundering from 2013 through August 2016 and as Executive Vice President, Business Integration, from 2011 to 2013. He joined BMO as interim Chief Financial Officer in 2008 and was appointed Chief Financial Officer in 2009. Prior to joining BMO, Mr. Robertson spent more than 35 years as a Chartered Professional Accountant, holding senior leadership roles at major accounting firms, including Vice Chair of Deloitte & Touche LLP (Toronto) from 2002 to 2008 and Canadian Managing Partner of Arthur Andersen LLP from 1994 to 2002. Mr. Robertson has previously served on the boards of BHC, Hydro One Limited, Turquoise Hill Resources Ltd. and Virtus Investment Partners, Inc. He holds a Bachelor of Arts (Honours) degree from the Ivey School of Business at the University of Western Ontario.

Mr. Paulson has served as an independent director of the Company since April 2022. He previously served on the board of the Company's parent, BHC, from June 2017 to May 2022 and rejoined the BHC board in June 2022, where he currently serves as Chairman. Mr. Paulson is President and Portfolio Manager and a director of Paulson Capital Inc., a private investment management firm specializing in global mergers, event arbitrage and credit strategies. He previously served as President and Portfolio Manager of Paulson & Co. Inc., which he founded in 1994. Prior to founding Paulson & Co. Inc., Mr. Paulson served as a Partner of Gruss Partners and as a Managing Director in the mergers and acquisitions group at Bear Stearns. Mr. Paulson has served as a director of Acadian Asset Management Inc. (formerly BrightSphere Investment Group plc), a publicly traded asset management holding company, since November 2018, and has served as Chairman of its board since April 2020. He also serves as Chairman of the board and as majority owner of Steinway Musical Instruments, Inc. and P.F. Chang's Holdings, Inc. In addition, Mr. Paulson serves as a director of the Princess Grace Foundation, the Preservation Foundation of Palm Beach and Lawfare Defense Fund Inc., and previously served as a director of American International Group Inc. from May 2016 to June 2017. Mr. Paulson holds a bachelor's degree in finance from New York University and an MBA from Harvard Business School. Current Public Company Directorships: Acadian Asset Management Inc. ; Bausch Health Companies Inc. Previous Public Company Directorships: American International Group Inc.

On August 6, 2026, Bausch + Lomb Corporation appointed Mr. Robert Chersi to its board of directors , effective August 5, 2026. From 2013 through August 2016, Mr. Robertson served as Executive Vice President and Head, Anti-Money Laundering, at BMO Financial Group, a diversified financial services organization. Prior to that role, he served as BMO's Executive Vice President, Business Integration, and as Vice Chair. He joined BMO as interim Chief Financial Officer in 2008 and was appointed Chief Financial Officer in 2009. Before joining BMO, Mr. Robertson spent more than 35 years as a Chartered Public Accountant. In this capacity, he held various senior positions with a number of major accounting firms, including Vice Chair, Deloitte & Touche LLP in Toronto, Canada, from 2002 to 2008, and Canadian Managing Partner, Arthur Andersen LLP, from 1994 to 2002. Mr. Robertson holds a Bachelor of Arts degree (Honours) from the Ivey School of Business at the University of Western Ontario. Mr. Robertson has served on the board of Hydro One Limited, a publicly traded electricity transmission and distribution utility serving Ontario, since August 2018, and since 2012 has served on the board of Turquoise Hill Resources, a publicly traded Canadian mineral exploration and development company. He has also been serving on the board of Bausch Health Companies since June 2016. Mr. Robertson previously served on the board of Virtus Investment Partners, Inc. from 2013 to August 2016.

On August 6, 2026, Bausch + Lomb Corporation appointed Ms. Barbara Trebbi to its board of directors , effective August 5, 2026. Barbara Trebbi, CFA, is an experienced public company director and investment management executive with more than 30 years of experience in global asset management, finance and corporate governance. She currently serves as an independent director of Acadian Asset Management Inc. (NYSE: AAMI), where she chairs the Compensation Committee and serves on the Audit Committee and Nominating & Governance Committee. Ms. Trebbi spent more than three decades in institutional investment management, most recently as Senior Partner of Mercator Asset Management LP, where she helped grow the firm's assets under management from approximately $2 billion to more than $13 billion. Earlier in her career, she served as Senior Vice President and Head of International Equities at Mackenzie Investment Management Inc. and was a member of the firm's Executive Committee. Ms. Trebbi also serves as Co-Chief Executive Officer of Landry Trebbi Investment Corp. and as a member of the Board of Trustees of Nova Southeastern University. Ms. Trebbi holds a Bachelor of Science in Business Administration (Finance) from the University of Florida and a Graduate Diploma in Accounting and Finance from the London School of Economics and Political Science. She holds the Chartered Financial Analyst designation.

On August 6, 2026, Bausch + Lomb Corporation appointed Thomas J. Appio to its board of directors , effective August 5, 2026. Thomas J. Appio, CEO, Bausch Health. Thomas J. Appio has been the Chief Executive Officer and a Director of Bausch Health Companies Inc. (BHC), the parent of Bausch + Lomb Corporation, since May 2022. He previously served as BHC's President & Co-Head, Bausch + Lomb/International and Executive Vice President, Company Group Chairman, International. Prior to its acquisition by BHC in 2013, Mr. Appio served in several positions with Bausch + Lomb, including as Vice President, North Asia/Japan and as Managing Director, Greater China and Japan. Prior to joining Bausch + Lomb, Mr. Appio served for 23 years with Schering-Plough in a wide range of leadership and operations responsibilities. Mr. Appio holds a Bachelor of Science in Accounting from Arizona State University, W.P. Carey School of Business.

On August 6, 2026, Bausch + Lomb Corporation appointed Dr. Laurence E. Paul,M.D. to its board of directors , effective August 5, 2026. Laurence E. Paul, M.D., is Co-Founder and Managing Principal of Laurel Crown Partners, a Pittsburgh-based private equity firm. Since co-founding the firm in 2001, Dr. Paul has led its investment strategy, transaction structuring and portfolio company governance across a range of industries, including healthcare, financial services, industrial manufacturing and specialty chemicals. In addition to his investment activities, Dr. Paul serves as Chairman of the Board of Fellows of Harvard Medical School and as a trustee or director of several healthcare and nonprofit organizations, including Children's Hospital Los Angeles and UPMC Children's Hospital of Pittsburgh. He also serves on the Board of Trustees of the Pro Football Hall of Fame and is a director of the Pittsburgh Steelers Football Club. Dr. Paul previously served in senior leadership roles with the American Red Cross, including Vice Chairman of its Board of Governors, and was recognized with the organization's Harriman Award for Distinguished Volunteer Service.

Mr. Bonnefoy has served as President, Surgical of the Company since June 2023, after previously serving as Senior Vice President, Surgical since November 2021. He has nearly 30 years of leadership experience in the ophthalmology industry and has been employed by Bausch + Lomb for more than two decades, including service as Vice President, Surgical, International from 2013 to 2021. Mr. Bonnefoy currently serves on the board of directors of Eye Med Technologies Ltd, a private company operating in the ophthalmic medical device sector. He previously served as Vice President, EMEA for Technolas Perfect Vision GmbH, a Bausch + Lomb company, from 2009 to 2013. From 2002 to 2008, Mr. Bonnefoy held roles with responsibility for surgical marketing and sales development in EMEA and for the surgical business unit in France. Mr. Bonnefoy holds a DESS degree in Microbiology from the Institut Pharmaceutique et Industrielle de Lyon (IPIL).

Mr. Frederick J. Munsch, Senior Vice President, Controller and Chief Accounting Officer of the company.